Trial reportCirculation2020
Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings.
Trial report in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 122 citations in OpenAlex.
- Baseline Computed Tomography Coronary Angiography and Polygenic Risk Profiles in Adults With Type 2 Diabetes: A Cross-Sectional Analysis From the VOLTAIRE Study.Diabetes, obesity & metabolism · 2026Trial
- Association of sarcopenic obesity with advanced cardiovascular-kidney-metabolic syndrome and incident cardiovascular disease: a longitudinal and cross-sectional study.Diabetology & metabolic syndrome · 2026Article
- Device innovation or systemic risk management?-rethinking priorities in diabetic percutaneous coronary intervention.Cardiovascular diagnosis and therapy · 2026Article
- Cardiovascular risk factor target control in Romanian adults with type 2 diabetes.Scientific reports · 2026Article
- Medication Adherence and Risks of Mortality and End-Organ Damage in Asian Patients with Type 2 Diabetes: A Cohort Study from Southern Taiwan.Biomedicines · 2026Article
- Cardio-Reno-Microvascular Phenotypes and Multifactorial Cardiometabolic Target Achievement in Type 2 Diabetes.Journal of clinical medicine · 2026Article
- Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.Diabetes, obesity & metabolism · 2026Article
- Association of remnant cholesterol with cardiovascular events and mortality in biopsy-proven diabetic kidney disease.Frontiers in endocrinology · 2026Article
- Article
- Improved sex-specific cardiovascular risk prediction with multi-omics data in people with type 2 diabetes.Cardiovascular diabetology · 2025Article
- Risk factor control in relation to mortality and life expectancy among people with type 2 diabetes: results from 3 nationwide cohort studies.Military Medical Research · 2025Article
- Contemporary Percutaneous Coronary Intervention in Diabetic Patients.Reviews in cardiovascular medicine · 2025Review
- Cancer as a novel risk factor for major cardiovascular adverse events in secondary prevention.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018).Journal of the American Heart Association · 2025Article
- Loneliness, social isolation and stroke risk in men and women with and without diabetes.BMC public health · 2025Article
- Association between multifactorial control and excess risk of liver diseases in type 2 diabetes: a prospective cohort study.BMJ open diabetes research & care · 2025Article
- Sodium Butyrate, A Gut Microbiota Derived Metabolite in Type 2 Diabetes Mellitus and Cardiovascular Disease: A Review.Cardiovascular & hematological agents in medicinal chemistry · 2025Review
- Article
- Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta-Analysis.Journal of diabetes · 2025Article
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundTo examine the association between the degree of risk factor control and cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-renal disease modifies these relationships.
methodsA retrospective cohort study using data from English practices from CPRD GOLD (Clinical Practice Research Datalink) and the SCI-Diabetes dataset (Scottish Care Information-Diabetes), with linkage to hospital and mortality data. We identified 101 749 with type 2 diabetes (T2D) in CPRD matched with 378 938 controls without diabetes and 330 892 with type 2 diabetes in SCI-Diabetes between 2006 and 2015. The main exposure was number of optimized risk factors: nonsmoker, total cholesterol ≤4 mmol/L, triglycerides ≤1.7 mmol/L, glycated haemoglobin (HbA1c) ≤53 mmol/mol (≤7.0%), systolic blood pressure <140mm Hg, or <130 mm Hg if high risk. Cox models were used to assess cardiovascular risk associated with levels of risk factor control.
resultsIn CPRD, the mean baseline age in T2D was 63 years and 28% had cardio-renal disease (SCI-Diabetes: 62 years; 35% cardio-renal disease). Over 3 years follow-up (SCI-Diabetes: 6 years), CVD events occurred among 27 900 (27%) CPRD-T2D, 101 362 (31%) SCI-Diabetes-T2D, and 75 520 (19%) CPRD-controls. In CPRD, compared with controls, T2D participants with optimal risk factor control (all risk factors controlled) had a higher risk of CVD events (adjusted hazard ratio, 1.21; 95% confidence interval, 1.12-1.29). In T2D participants from CPRD and SCI-Diabetes, pooled hazard ratios for CVD associated with 5 risk factors being elevated versus optimal risk factor control were 1.09 (95% confidence interval, 1.01-1.17) in people with cardio-renal disease but 1.96 (95% confidence interval, 1.82-2.12) in people without cardio-renal disease. People without cardio-renal disease were younger and more likely to have likely to have suboptimal risk factor control but had fewer prescriptions for risk factor modifying medications than those with cardio-renal disease.
conclusionsOptimally managed people with T2D have a 21% higher CVD risk when compared with controls. People with T2D without cardio-renal disease would be predicted to benefit greatly from CVD risk factor intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.